4 results about "Platelet aggregation inhibitor" patented technology

This invention relates to a pharmaceutical composition and its application for treating acute ischemic stroke. The pharmaceutical composition for treating acute ischemic stroke comprises separately packaged tissue-type plasminogen activator citPA5 and a platelet aggregation inhibitor. Its beneficial effects include significantly improving cerebral blood flow recovery, shortening thrombolysis time, reducing infarct volume, and improving neurological function without increasing the risk of bleeding, demonstrating a good synergistic thrombolytic effect.

This invention belongs to the field of pharmaceutical technology and relates to platelet aggregation inhibitors, their preparation methods, and applications. This invention provides compounds of general formula I and their pharmaceutically usable salts, tautomers, and pharmaceutically usable solvates, wherein R1, R2, and n are as described in the claims and specification. This invention also provides intermediates for preparing compounds of general formula I and their pharmaceutically usable salts, tautomers, and pharmaceutically usable solvates. The compounds of general formula I of this invention, their pharmaceutically usable salts, tautomers, pharmaceutically usable solvates, or pharmaceutical compositions thereof have platelet-inhibiting activity and can be used to prepare platelet aggregation inhibitors, which can be used to treat thromboembolic diseases, especially cerebral infarction.

This invention relates to 2-phenylpyrimidine platelet aggregation inhibitors, their preparation methods, and their application in the preparation of drugs for treating thrombotic diseases, belonging to the field of pharmaceutical technology. The compounds of this invention, their pharmaceutically usable salts, tautomers, and pharmaceutically usable solvates have the structures shown in Formula I, wherein R1-R5 and A are as described in the claims and specification. The compounds of this invention, their pharmaceutically usable salts, tautomers, pharmaceutically usable solvates, and their pharmaceutical compositions have platelet aggregation inhibitory activity and can be used to prepare drugs for the prevention and treatment of thrombotic diseases.

This invention provides a digital twin-based system and method for predicting the risk of cerebrovascular diseases in high-altitude environments, belonging to the field of cerebrovascular disease risk simulation and prediction technology. The system includes: an equipment control module, an oxygen control module, and an oxygen-pressure coupling control module. First, the oxygen concentration monitoring strategy of the oxygen regulation equipment is dynamically optimized based on concentration accuracy parameters and environmental impact parameters. Then, gas regulation dynamic factors are monitored in real time, and the equipment control strategy of the oxygen regulation equipment is dynamically adjusted based on these factors and concentration accuracy assessment values. Finally, the wind speed is dynamically adjusted according to the monitored gas injection status parameters, oxygen regulation is triggered based on oxygen equilibrium time and pressure equilibrium time, and cerebrovascular disease risk is predicted based on the adjusted oxygen regulation equipment and the hypobaric chamber. The high-fidelity high-altitude environment simulation based on digital twins significantly improves the accuracy of the cerebrovascular disease risk prediction model.